未登录

K

Karen Miotto

University of California Los Angeles

H指数:36

被引数:5,566

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Suvorexant for alcohol use disorder and post-traumatic stress disorder: study protocol for a phase II randomized clinical trial

苏沃雷塞用于酒精使用障碍和创伤后应激障碍：一项II期随机临床试验研究方案

IF2

2026-02-030

PRE

Professional Coaching to Reduce Physician Burnout: A Randomized Clinical Trial

专业教练干预减轻医师职业倦怠：一项随机临床试验

Journal of General Internal Medicine

IF4.2

2025-07-110

OAAI

Inflammatory endotoxin challenge in individuals with alcohol use disorder and controls

酒精使用障碍个体和对照组中的炎症内毒素挑战

alcohol clinical and experimental research

IF0

2025-06-010

PRE

Effects of a novel GABA-B positive allosteric modulator, ASP8062, on alcohol cue-elicited craving and naturalistic alcohol consumption in a multisite randomized, double-blind, placebo-controlled trial

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH

IF2.7

2024-12-020

OA

Does sex moderate the effects of early life stress on peripheral inflammation in alcohol use disorder? A preliminary investigation

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2024-12-010

PRE

A practice quit model to test early efficacy of medications for alcohol use disorder in a randomized clinical trial

PSYCHOPHARMACOLOGY

IF3.3

2023-11-283

PRE

Effects of ibudilast on central and peripheral markers of inflammation in alcohol use disorder: A randomized clinical trial

Ibudisast对酒精使用障碍患者炎症的中枢和外周标志物的影响: 一项随机临床试验

ADDICTION BIOLOGY

IF2.6

2022-05-1114

OA

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

IF14.4

2022-02-0886

OAAI

Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial

AMERICAN JOURNAL OF PSYCHIATRY

IF14.7

2021-09-0123

OA

Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2021-08-016

OAAI

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial

TRANSLATIONAL PSYCHIATRY

IF6.2

2021-06-1254

OAAI

Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent

DRUG AND ALCOHOL DEPENDENCE

IF3.6

2019-07-019

OAAI

Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder

JOURNAL OF ADDICTION MEDICINE

IF3.2

2019-01-0121

OAAI

Differences in the subjective and motivational properties of alcohol across alcohol use severity: application of a novel translational human laboratory paradigm

NEUROPSYCHOPHARMACOLOGY

IF7.1

2018-05-0840

OAAI

Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial

ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH

IF2.7

2018-02-0115

OAAI

High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System

JOURNAL OF ADDICTION MEDICINE

IF3.2

2017-07-01151

OAAI

Chronic pain among patients with opioid use disorder: Results from electronic health records data

JOURNAL OF SUBSTANCE ABUSE TREATMENT

IF4

2017-06-01155

OAAI

Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial

NEUROPSYCHOPHARMACOLOGY

IF7.1

2017-01-16103

OAAI

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study

NEUROPSYCHOPHARMACOLOGY

IF7.1

2015-03-2457

OAAI

Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings

PSYCHOPHARMACOLOGY

IF3.3

2014-04-1546

OA